The pharmacodynamics of an investigational glycopeptide, LY333328 (LY), alone and in combination with gentamicin, against one vancomycin-susceptible and two vancomycin-resistant Enterococcus faecium strains were studied with a multiple-dose, in vitro pharmacodynamic model (PDM). Dose-range data for the PDM studies were obtained from static time-kill curve studies. In PDM experiments conducted over 48 h, peak LY concentrations of 0.1x and 1x the MIC every 24 h and peak gentamicin concentrations of 18 μg/ml every 24 h (Gq24h) and 6 μg/ml every 8 h (Gq8h) were studied alone and in the four possible LY-gentamicin combinations. Compared to either antibiotic alone, LY- gentamicin combination regimens produced significantly higher apparent killing rates (KRs) calculated during the initial 2 h postdosing. The mean KRs for LY or gentamicin alone versus those for the LY-gentamicin combination regimens were 0.35 ± 0.55 log10 CFU/ml/h (95% confidence interval [CI(95%)], 0 to 0.70) and 1.46 ± 0.71 log10 CFU/ml/h (CI(95%), 1.01 to 1.91), respectively (P < 0.0001). Bacterial killing at 48 h (BK48), which was calculated by subtracting the bacterial counts at 48 h from the initial inoculum, with a negative value indicating net growth, was also significantly greater. The mean BK48s were -0.69 ± 0.44 log10 CFU/ml (CI(95%), -0.41 to -0.97) and 3.72 ± 2.28 log10 CFU/ml (CI(95%), 2.28 to 5.17) for LY or gentamicin alone versus LY-gentamicin combination regimens, respectively (P < 0.0001). None of the 12 regimens with LY or gentamicin alone but 75% (9 of 12) of the LY-gentamicin combination regimens were bactericidal. Eighty- three percent (10 of 12) of the LY-gentamicin combination regimens also demonstrated synergy. No significant differences between the pharmacodynamics of LY-gentamicin combination regimens containing Gq24h versus those containing Gq8h were detected.
CITATION STYLE
Zelenitsky, S. A., Booker, B., Laing, N., Karlowsky, J. A., Hoban, D. J., & Zhanel, G. G. (1999). Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple- dose, in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy, 43(3), 592–597. https://doi.org/10.1128/aac.43.3.592
Mendeley helps you to discover research relevant for your work.